The quantitative and qualitative surfactant defect that develops during the acute respiratory distress syndrome (ARDS) is associated with considerable end expiratory alveolar collapse. The resultant cyclical alveolar collapse and re-recruitment that occurs during ventilation leads to significant shear stress and is associated with worsening lung injury. Higher levels of positive end-expiratory pressure (PEEP) may prevent alveolar collapse and reduce ventilator-induced lung injury. In this study the authors attempted to assess the impact of increasing PEEP on the clinical outcomes of patients with acute lung injury (ALI) and ARDS Design Prospective, randomised, non-blinded, controlled trial. Study powered (89%) to detect a 10% reduction in mortality. Independent data and safety monitoring board conducted interim analysis after each 250 patients. Asymmetric stopping boundaries (with a two sided-sided α =0.05) were included to allow early termination if the trial demonstrated a survival advantage to higher PEEP or a low probability of survival advantage (futility stopping rule).
Patients 549 mechanically ventilated patients with ALI and ARDS from the 23 hospitals of the National Heart, Lung, and Blood institute (NHLBI) ARDS Clinical Trials Network. Inclusion criteria: 1) American-European Consensus Conference definition for ALI/ARDS, 2) < 36 hours since eligibility criteria met. Exclusion criteria: Age less than 13 years, body weight greater than 1kg per centimetre of body height, increased intracranial pressure, severe chronic respiratory disease or a coexisting condition associated with an estimated mortality of greater than 50 percent.
Intervention
Patients were ventilated with volume assist/control to a tidal volume of 6ml per kilogram ideal body weight and a plateau pressure of 30 cm of water or less (tidal volume was reduced if this plateau pressure was exceeded). Inspired oxygen concentration and PEEP were adjusted in fixed combinations to achieve an oxygenation goal of 55-80mmHg (7.3-10.7 kPa) or arterial oxyhaemoglobin saturation (measured by pulse oximetry) of 88 to 95 percent. Each patient was randomised to either a high PEEP or low PEEP protocol (all other ventilator procedures were identical between the two groups). The low PEEP group were ventilated in exactly the same way as the low tidal volume arm of the previous ARDSnet trial1.
Results
At the first interim analysis the difference in mean PEEP levels between the study groups was only 3.8 cm H 2 O and this was significantly less than anticipated. The higher PEEP strategy was therefore altered to include a minimum PEEP of 14 cm H 2 0 for at least 48 hours (the data collected before this protocol change was included in the final data analysis). The trial was stopped at the second interim analysis, on the basis of the futility rule. The final mean (± SD) PEEP values on day 1 to 4 were 8.3 ±3.2cm of water in the lower PEEP group and 13.2±3.5cm of water in the higher PEEP group (P < 0.001). The rates of death before hospital discharge were 24.9 percent and 27.5 percent, respectively (p=0.48). From day 1 to day 28, breathing was unassisted for a mean of 14.5 ±10.4 days in the lower-PEEP group and 13.8 ±10.6 in the higher PEEP group (P=0.50).
Conclusions
Patients with ALI or ARDS who receive mechanical ventilation to a tidal volume goal of 6 ml per kilogram of predicted body weight obtain no clinically significant outcome benefit whether lower or higher PEEP levels are used.
Are the results of the study valid? Primary Guides
Was the assignment of patients to treatments randomised? Was the randomisation list concealed? Yes. Patients were stratified according to hospital and then randomised by a centralised voice activated computer system.
Were all patients who entered the trial accounted for at its conclusion? Were they analysed in the groups to which they were randomised? Yes.
Secondary Guides
Were the patients and clinicians kept 'blind' to which treatment was being received? No.
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Aside from the experimental treatment, were the groups treated equally? No. The first 80 patients in the higher PEEP group received one or two daily recruitment procedure for the first four days of treatment. Recruitment manoeuvres were stopped at this stage, as there appeared to be no improvement in mean arterial oxygenation.
Were the groups similar at the start of the trial? No. The higher PEEP group were older and had lower (worse) PaO 2 :FiO 2 ratios at enrolment (P=0.004 and 0.003 respectively).
In order to try and adjust for baseline variances between the two groups a forward stepwise selection scheme was performed on previous ARDSnet data 1 in an attempt to identify baseline predictors of mortality. This data was then used in a logistic model to predict mortality in each patient. The average predicted mortality provided an estimated mortality for both groups if the baseline variables had been equal.
If subgroup analysis has been done and conclusions made:
Two significant additional sets of data analysis were performed on the raw data. First, the mortality figures were reassessed following mortality adjustment (as outlined above). Second, data pre and post high PEEP protocol changes were examined both collectively and then individually.
Do they really make biologic and clinical sense?
Yes. The evidence behind the high PEEP arm was based on a previous study 2 in which a minimum PEEP of 14 cmH 2 0 was required. The first interim analysis demonstrated that this PEEP level had not been achieved in the higher PEEP group.
Is the qualitative difference both clinically (beneficial for some but useless or harmful for others) and statistically significant?
No. Neither of these additional data analysis provided any statistically significant results.
3. Was this difference hypothesised before the study began (rather than the product of dredging the data) and has it been confirmed in other, independent studies? It is unclear whether a mortality prediction calculation was designed before or after baseline differences were noted.
Are the valid results of this trial important?
Yes. The trial demonstrates that a higher PEEP can initially improve oxygenation and compliance. Despite these short-term improvements no clinically significant long-term outcome benefit appears to exist.
Higher PEEP, proning 3 and nitric oxide 4 have all failed to improve mortality despite oxygenation improvements. This calls into question the use of oxygenation indices as a surrogate for successful treatment of ARDS.
Do these results apply to our patients?
Whilst the baseline patient characteristics and disease aetiology are similar to the ARDS population of a typical UK ICU, the majority of patients in this country are ventilated using pressure control ventilation (PCV). Simple equivalence between PCV and the volume-controlled ventilation used by ARDSnet cannot be assumed.
Comment
Following the initial success of the first ARDSnet trial in 2000, the outcome of this trial was long awaited. The negative results are inevitably a major disappointment. A number of explanations can be hypothesised as to why no difference in mortality could be demonstrated; benefits of PEEP are minor when combined with a low tidal volume approach to ventilation, the two patient groups had different baseline demographics, the differences in PEEP were insufficient, the patients were not sick enough (PaO 2 :FiO 2 ratios were too high) or the trial was terminated prematurely. However, we must accept that the evidence provided by this trial does not support an improved mortality based on a higher level of PEEP in ARDS.
This trial also opens to question the whole question of how we treat ARDS as a disease. A diagnosis of ARDS is made entirely on consensus clinical characteristics. The disease does not have a unique defining pathophysiological basis and as such incorporates a wide range of heterogeneous patients. There is increasing evidence that within the diagnostic umbrella of ARDS exists a number of disease subdivisions and so it is not surprising that a single treatment does not benefit all patients. In the future ARDS may be sub-classified according to disease aetiology (pulmonary or extrapulmonary 5 ), morphology or response to therapy and in some of these sub-groups high PEEP may yet turn out to be beneficial. However, the studies to examine these groups would be extremely difficult to perform.
Conclusion
This paper highlights several key points; firstly, in clinical research even a well-funded, well-designed study can produce surprising results that require difficult decisions to be made whilst a trial is ongoing. Given the predicament that these authors faced after the first interim analysis they had little choice but to continue as they did. Failure to do this could have potentially resulted in the collapse of ARDSnet or a completely worthless trial. Secondly, improvement in oxygenation indices cannot be used as a surrogate endpoint for treatment success. Thirdly, a simple prescriptive fixed inspired oxygen concentration/PEEP combination cannot be justified. Fourthly, after the difficulties of this trial, defining "optimal" PEEP in ARDS is likely to remain elusive for the foreseeable future. Finally, it should always be remembered that a negative trial is not necessarily a bad trial. 
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